You Searched For: Electroporation Systems

Upstream processing for cell therapy Compared to production volumes associated with other biologics (e.g. mAbs: 2000L to 10000L) cell therapy production volumes are more commonly between 1L to 10L. Even the quality parameters are different. Instea...

Upstream processing for cell therapy Compared to production volumes associated with other biologics (e.g. mAbs: 2000L to 10000L) cell therapy production volumes are more commonly between 1L to 10L. Even the quality parameters are different. Instea...

Upstream processing for cell therapy Compared to production volumes associated with other biologics (e.g. mAbs: 2000L to 10000L) cell therapy production volumes are more commonly between 1L to 10L. Even the quality parameters are different. Instea...

Upstream processing for cell therapy Compared to production volumes associated with other biologics (e.g. mAbs: 2000L to 10000L) cell therapy production volumes are more commonly between 1L to 10L. Even the quality parameters are different. Instea...

Upstream processing for cell therapy Compared to production volumes associated with other biologics (e.g. mAbs: 2000L to 10000L) cell therapy production volumes are more commonly between 1L to 10L. Even the quality parameters are different. Instea...

Upstream processing for mAbs Developing and manufacturing mAbs has moved away from a dependency on raw materials of animal origin. Our biochemical components and supplements are animal component-free to meet the needs of these applications. Produc...

Upstream processing for mAbs Developing and manufacturing mAbs has moved away from a dependency on raw materials of animal origin. Our biochemical components and supplements are animal component-free to meet the needs of these applications. Produc...

Upstream processing for mAbs Developing and manufacturing mAbs has moved away from a dependency on raw materials of animal origin. Our biochemical components and supplements are animal component-free to meet the needs of these applications. Produc...

Upstream processing for vaccines Optimal production of vaccines is achieved in mammalian expression and insect systems using cell lines that are anchorage-dependent or suspension enabled. For most vaccines optimal production is achieved in mammali...

Upstream processing for vaccines Optimal production of vaccines is achieved in mammalian expression and insect systems using cell lines that are anchorage-dependent or suspension enabled. For most vaccines optimal production is achieved in mammali...

Upstream processing for mAbs Developing and manufacturing mAbs has moved away from a dependency on raw materials of animal origin. Our biochemical components and supplements are animal component-free to meet the needs of these applications. Produc...

Upstream processing for mAbs Developing and manufacturing mAbs has moved away from a dependency on raw materials of animal origin. Our biochemical components and supplements are animal component-free to meet the needs of these applications. Produc...

Upstream processing for mAbs Developing and manufacturing mAbs has moved away from a dependency on raw materials of animal origin. Our biochemical components and supplements are animal component-free to meet the needs of these applications. Produc...

Upstream processing for mAbs Developing and manufacturing mAbs has moved away from a dependency on raw materials of animal origin. Our biochemical components and supplements are animal component-free to meet the needs of these applications. Produc...

Upstream processing for cell therapy Compared to production volumes associated with other biologics (e.g. mAbs: 2000L to 10000L) cell therapy production volumes are more commonly between 1L to 10L. Even the quality parameters are different. Instea...

Upstream processing for cell therapy Compared to production volumes associated with other biologics (e.g. mAbs: 2000L to 10000L) cell therapy production volumes are more commonly between 1L to 10L. Even the quality parameters are different. Instea...